Wednesday, July 20, 2011 11:26:06 AM
Stories You Might Like
By Val Brickates Kennedy
AMAG ALTH
BOSTON (MarketWatch) -- Shares of AMAG Pharmaceuticals /quotes/zigman/107237/quotes/nls/amag AMAG -13.95% dropped 14% to $16.46 on Wednesday following news that it plans to merge with Allos Therapeutics /quotes/zigman/81880/quotes/nls/alth ALTH -1.94% in an all-stock deal valued at around $686 million. Following the merger, AMAG shareholders will hold a 61% stake in the new company, while Allos stockholders will have 39%. The combined company will be headquartered in Lexington, Mass., and will be renamed "to reflect its strategic focus," the companies said. The deal is expected to close in the fourth quarter. Shares of Allos were down 1%.
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM